391 related articles for article (PubMed ID: 23718260)
41. Malnutrition-inflammation syndrome is associated with endothelial dysfunction in peritoneal dialysis patients.
Aguilera A; Sánchez-Tomero JA; Bajo MA; Ruiz-Caravaca ML; Alvarez V; del Peso G; Herranz A; Cuesta MV; Castro MJ; Selgas R
Adv Perit Dial; 2003; 19():240-5. PubMed ID: 14763071
[TBL] [Abstract][Full Text] [Related]
42. Peritoneal solute transport rate as an independent risk factor for total and cardiovascular mortality in a population of peritoneal dialysis patients.
Janda K; Krzanowski M; Dumnicka P; Kuśnierz-Cabala B; Miarka P; Sułowicz W
Adv Perit Dial; 2014; 30():15-20. PubMed ID: 25338416
[TBL] [Abstract][Full Text] [Related]
43. Elevated osteoprotegerin is associated with inflammation, malnutrition and new onset cardiovascular events in peritoneal dialysis patients.
Koo HM; Do HM; Kim EJ; Lee MJ; Shin DH; Kim SJ; Oh HJ; Yoo DE; Kim JK; Park JT; Han SH; Kang SW; Choi KH; Yoo TH
Atherosclerosis; 2011 Dec; 219(2):925-30. PubMed ID: 22015178
[TBL] [Abstract][Full Text] [Related]
44. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of peritoneal transport properties at onset of peritoneal dialysis and longitudinal follow-up.
Clerbaux G; Francart J; Wallemacq P; Robert A; Goffin E
Nephrol Dial Transplant; 2006 Apr; 21(4):1032-9. PubMed ID: 16364990
[TBL] [Abstract][Full Text] [Related]
46. Intraperitoneal interleukin-6 levels predict peritoneal solute transport rate: a prospective cohort study.
Yang X; Zhang H; Hang Y; Yan H; Lin A; Huang J; Ni Z; Qian J; Fang W
Am J Nephrol; 2014; 39(6):459-65. PubMed ID: 24854010
[TBL] [Abstract][Full Text] [Related]
47. Differences in peritoneal equilibration test results in patients aged above or below 60 years.
Grzegorzewska AE; Leander M; Mariak I
Adv Perit Dial; 2002; 18():33-9. PubMed ID: 12402583
[TBL] [Abstract][Full Text] [Related]
48. Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: their relationship with transport parameters.
Lai KN; Lai KB; Szeto CC; Ho KK; Poon P; Lam CW; Leung JC
Am J Kidney Dis; 1997 May; 29(5):699-705. PubMed ID: 9159303
[TBL] [Abstract][Full Text] [Related]
49. Dialysate copeptin and peritoneal transport in incident peritoneal dialysis patients.
Fijałkowski M; Safranow K; Lindholm B; Ciechanowski K; Muraszko AM; Dołęgowska B; Dołęgowska K; Golembiewska E
Int Urol Nephrol; 2019 Sep; 51(9):1667-1673. PubMed ID: 31187425
[TBL] [Abstract][Full Text] [Related]
50. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis.
Chung SH; Heimbürger O; Stenvinkel P; Bergström J; Lindholm B
Nephrol Dial Transplant; 2001 Nov; 16(11):2240-5. PubMed ID: 11682675
[TBL] [Abstract][Full Text] [Related]
51. Icodextrin and intraperitoneal inflammation.
Moriishi M; Kawanishi H
Perit Dial Int; 2008 Jun; 28 Suppl 3():S96-S100. PubMed ID: 18552274
[TBL] [Abstract][Full Text] [Related]
52. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients.
Visser CE; Brouwer-Steenbergen JJ; Betjes MG; Koomen GC; Beelen RH; Krediet RT
Nephrol Dial Transplant; 1995; 10(1):64-9. PubMed ID: 7724031
[TBL] [Abstract][Full Text] [Related]
53. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.
Opatrna S; Lysak D; Trefil L; Parker C; Topley N
Perit Dial Int; 2012; 32(1):37-44. PubMed ID: 22302924
[TBL] [Abstract][Full Text] [Related]
54. Lack of correlation between baseline peritoneal membrane status and pre-dialytic characteristics.
Balafa O; Vlahu C; Sampimon D; Coester AM; Struijk DG; Krediet RT
Adv Perit Dial; 2010; 26():16-20. PubMed ID: 21348373
[TBL] [Abstract][Full Text] [Related]
55. In vivo and in vitro effects of amino-acid-based and bicarbonate-buffered peritoneal dialysis solutions with regard to peritoneal transport and cytokines/prostanoids dialysate concentrations.
Plum J; Fusshöller A; Schoenicke G; Busch T; Erren C; Fieseler C; Kirchgessner J; Passlick-Deetjen J; Grabensee B
Nephrol Dial Transplant; 1997 Aug; 12(8):1652-60. PubMed ID: 9269644
[TBL] [Abstract][Full Text] [Related]
56. Peritoneal inflammation and fibrosis in C-reactive protein transgenic mice undergoing peritoneal dialysis solution treatment.
Poon PY; Lan HY; Kwan BC; Huang XR; Chow KM; Szeto CC; Li PK
Nephrology (Carlton); 2017 Feb; 22(2):125-132. PubMed ID: 26857687
[TBL] [Abstract][Full Text] [Related]
57. Effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
Park JW; Kang SH; Do JY
Iran J Kidney Dis; 2014 Jan; 8(1):58-64. PubMed ID: 24413723
[TBL] [Abstract][Full Text] [Related]
58. Dialysate cancer antigen 125 in long-term peritoneal dialysis patients.
Ditsawanon P; Supasyndh O; Aramwit P
Clin Exp Nephrol; 2014 Feb; 18(1):10-5. PubMed ID: 23757048
[TBL] [Abstract][Full Text] [Related]
59. Serum cystatin C: a surrogate marker for the characteristics of peritoneal membrane in dialysis patients.
Al-Wakeel JS; Hammad D; Memon NA; Tarif N; Shah I; Chaudhary A
Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):227-31. PubMed ID: 19237809
[TBL] [Abstract][Full Text] [Related]
60. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
